Clinical Research Directory
Browse clinical research sites, groups, and studies.
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
Official title: A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
443
Start Date
2021-07-23
Completion Date
2027-05-31
Last Updated
2025-09-09
Healthy Volunteers
No
Conditions
Interventions
camrelizumab; famitinib malate
Camrelizumab intravenously ; Famitinib Orally
platinum-based chemotherapy
Physician's choice chemotherapy
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China